Drospirenone And Ethinyl Estradiol

Introduction Overview

Generic Name

drospirenone and ethinyl estradiol

Brand Name

Yaz

Dosage Form

Oral tablet

Drug Class

Contraceptives

Pharmacokinetics

Absorption:
Drospirenone and ethinyl estradiol, the active ingredients of Yaz, are well absorbed following oral administration. Ethinyl estradiol is rapidly absorbed and reaches peak plasma concentrations typically within 1 to 2 hours after ingestion. Drospirenone displays a similar absorption profile, with plasma peak concentrations occurring approximately 1 to 3 hours post-dose. The bioavailability of drospirenone is approximately 76%, while ethinyl estradiol has a bioavailability of about 38 to 48% due to first-pass metabolism in the liver. Food intake does not significantly affect the absorption of either component, allowing flexible administration with or without food.

Distribution:
Both drospirenone and ethinyl estradiol are extensively bound to plasma proteins, predominantly albumin. Drospirenone is about 95-97% bound, whereas ethinyl estradiol is approximately 98-99% protein bound. Drospirenone does not bind to sex hormone binding globulin (SHBG) or corticosteroid-binding globulin, whereas ethinyl estradiol induces SHBG synthesis. The volume of distribution for drospirenone ranges between 3.7 to 6.0 L/kg, indicating substantial tissue distribution. Ethinyl estradiol similarly has a high volume of distribution, consistent with widespread tissue penetration. Both drugs cross the placental barrier and are detected in low concentrations in breast milk.

Metabolism:
Drospirenone undergoes extensive hepatic metabolism primarily via hydroxylation and subsequent conjugation to form inactive metabolites. Cytochrome P450 isoenzyme CYP3A4 plays a critical role in drospirenone metabolism. Ethinyl estradiol is metabolized mainly in the liver via hydroxylation by CYP3A4 and conjugation (glucuronidation and sulfation). Its metabolites undergo enterohepatic recirculation, contributing to prolonged activity. Both components are subject to first-pass metabolism which influences their systemic availability.

Elimination:
Drospirenone elimination occurs via renal and fecal routes predominantly as metabolites; less than 3% is excreted unchanged. The elimination half-life of drospirenone is approximately 30 hours, permitting once-daily dosing. Ethinyl estradiol has a half-life ranging from 13 to 27 hours, supporting steady-state concentrations with daily administration. Ethinyl estradiol and its metabolites are primarily eliminated in the urine and feces. The steady state is generally achieved after 7 days of continuous dosing. Factors such as hepatic impairment, age, and concomitant medications can influence the pharmacokinetics and, consequently, the efficacy and safety of Yaz.

Dosage Forms

Available Dosage Forms:
- Oral tablet containing 3 mg drospirenone and 0.02 mg ethinyl estradiol.

Dosages for Adults and Adolescents:
- One tablet taken orally once daily at the same time each day for 24 consecutive days, followed by 4 days of inactive tablets (placebo) to complete a 28-day cycle.
- Initiation can be on the first day of the menstrual cycle or the first Sunday after menstruation begins.
- Back-up contraception recommended during the first 7 days of initial use or after a break of more than 7 days.

Specific Patient Populations:
- Use in females aged 14 years and older who have commenced menstruation.
- Not recommended for use during pregnancy or breastfeeding due to potential risks to the fetus and infant.
- Dosage adjustments are not typically necessary based on age or renal function, but caution advised in patients with renal impairment due to the potassium-sparing effects of drospirenone.
- Contraindicated in patients with severe hepatic impairment.

Clinical Guidelines:
- Adherence to daily dosing with no more than 24 hours between doses is critical to maintain contraceptive efficacy.
- Missed dose instructions involve taking the missed pill as soon as possible and using alternative contraception for 7 days if pills are missed consecutively, detailed in the patient leaflet.
- Temporary discontinuation recommended prior to major surgery or periods of prolonged immobilization to reduce thrombosis risk.

Mechanism Of Action

Yaz combines drospirenone, a synthetic progestin with anti-mineralocorticoid and anti-androgenic properties, and ethinyl estradiol, a synthetic estrogen, to exert multifaceted contraceptive and therapeutic effects. Primarily, this medication prevents ovulation by suppressing the hypothalamic-pituitary-ovarian axis. Drospirenone and ethinyl estradiol inhibit the secretion of gonadotropins—luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—thereby preventing the LH surge essential for ovulation.

Beyond ovulation inhibition, Yaz induces alterations in cervical mucus, increasing its viscosity, which restricts sperm penetration into the uterus and reduces fertilization likelihood. Additionally, it modifies the endometrial lining, creating an environment less receptive to implantation of a fertilized ovum, further enhancing contraceptive efficacy. The progestin component counteracts estrogen-mediated endometrial proliferation, stabilizing the uterine lining and reducing breakthrough bleeding.

Drospirenone's unique pharmacological profile includes aldosterone receptor antagonism, conferring potassium-sparing diuretic effects. This property helps mitigate estrogen-induced fluid retention, contributing to decreased bloating and weight gain commonly associated with combined oral contraceptives. Its anti-androgenic activity improves acne symptoms by competitively inhibiting androgen receptors and reducing sebaceous gland activity.

Comparatively, drospirenone distinguishes Yaz from other combined oral contraceptives containing different progestins without anti-mineralocorticoid effects. Clinical trials demonstrate comparable contraceptive efficacy with added benefits in reducing premenstrual dysphoric disorder symptoms, emotional lability, and moderate acne. This multi-targeted mechanism substantiates Yaz's use both as a contraceptive and as a therapy for hormonal and dermatologic conditions in reproductive-age women.

Pharmacological Actions

Inhibition of ovulation via suppression of hypothalamic-pituitary-gonadal axis.
Thickening of cervical mucus to impede sperm penetration.
Endometrial lining alterations making implantation less likely.
Anti-mineralocorticoid activity reducing fluid retention through aldosterone receptor antagonism.
Anti-androgenic effects improving acne by inhibiting androgen receptor activity.
Regulation of menstrual cycle reducing breakthrough bleeding and menstrual irregularities.
Reduction of symptoms associated with premenstrual dysphoric disorder (PMDD).
Potassium-sparing diuretic effect through drospirenone component.
Hormonal modulation balancing estrogen and progesterone levels in reproductive-aged women.
Prevention of follicular development and ovum maturation.
Modulation of sex hormone binding globulin (SHBG) levels impacting circulating androgen availability.
Demonstration of contraceptive efficacy comparable to other combined oral contraceptives.
Improvement in acne via sebaceous gland suppression due to anti-androgenic properties.
Stabilization of the endometrium to decrease menstrual pain and heavy bleeding.
Potential mood stabilization effects beneficial in PMDD management.

Therapeutic Or Clinical Uses

Prevention of pregnancy as an oral combined hormonal contraceptive.
Treatment of moderate acne vulgaris in females aged 14 years and older who desire contraception.
Management of symptoms associated with premenstrual dysphoric disorder (PMDD), including mood disturbances and physical symptoms.
Regulation of menstrual cycles in women with irregular menses.
Reduction of dysmenorrhea and menstrual-related pain.
Decreasing heavy menstrual bleeding and menstrual irregularities.
Treatment option for women requiring contraception who benefit from anti-mineralocorticoid effects to reduce fluid retention.
Improvement of hormonal acne by decreasing androgenic stimulation of sebaceous glands.
Management of cyclic mood symptoms and irritability related to hormonal fluctuations.
Off-label use for managing mild hirsutism due to anti-androgenic properties.
Potential reduction of ovarian cyst formation by suppressing ovulation.
As part of hormone regulation therapy in reproductive health settings.
Support in contraceptive planning post-partum after appropriate waiting period.
Alternative for women intolerant to other progestins without drospirenone’s favorable side effect profile.
Adjunct in multifactorial treatment strategies for conditions exacerbated by hormonal imbalances.

Side Or Adverse Effects

Nausea and vomiting commonly reported during initial treatment phase.
Breast tenderness and sensitivity.
Headache including migraine exacerbation or new onset.
Mood changes including irritability and depressive symptoms.
Weight gain or fluid retention due to hormonal changes.
Skin darkening or melasma-like pigmentation changes.
Menstrual irregularities such as breakthrough bleeding or spotting.
Decreased libido or changes in sexual desire.
Increased risk of venous thromboembolism (blood clots), particularly during initial treatment or when restarting after interruption.
Elevated blood pressure or related cardiovascular events including stroke and heart attack.
Potential hyperkalemia associated with drospirenone’s potassium-sparing properties.
Allergic reactions manifested by rash, hives, or angioedema.
Symptoms suggesting liver dysfunction such as jaundice, dark urine, or fatigue.
Visual disturbances including blurred or sudden vision loss.
Swelling of extremities indicating possible thrombosis.

Precautions

Avoid use during pregnancy and in early postpartum period (recommend waiting at least 4 weeks post-delivery).
Caution in patients with risk factors for thrombosis including obesity, smoking, diabetes, hypertension, and dyslipidemia.
Regular monitoring of blood pressure recommended, especially in hypertensive patients.
Periodic assessment of potassium levels in patients at risk for hyperkalemia or taking potassium supplements.
Not recommended in women over 35 years who smoke due to significantly increased cardiovascular risk.
Use cautiously in patients with history of migraine, especially with aura.
Discontinue prior to major surgery or prolonged immobilization to reduce thrombotic risk.
Avoid concurrent use with enzyme-inducing drugs that may reduce contraceptive efficacy.
Discuss potential mood changes with patients with a history of depression.
Monitor patients with liver, kidney impairment or metabolic disorders closely due to altered drug metabolism.
Educate patients regarding signs of thromboembolism and to seek immediate medical care if symptoms occur.
Avoid use if unexplained vaginal bleeding occurs until evaluated by a healthcare provider.
Inform patients about the potential reduction in breast milk production during breastfeeding.
Review all concomitant medications to assess for possible interactions reducing efficacy or increasing adverse effects.
Advise adherence to daily dosing schedule to maintain effectiveness.

Warnings

Significantly increased risk of thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction.
Do not use in women over 35 who smoke due to heightened cardiovascular risk.
Discontinue use immediately if signs of blood clots occur, including leg pain/swelling, chest pain, sudden shortness of breath, or neurological symptoms.
Avoid use in patients with uncontrolled hypertension or history of cardiovascular disease.
Potential for severe liver dysfunction and rare cases of liver tumors.
Possibility of increased blood pressure; patients should be monitored regularly.
Possible worsening of migraine headaches, especially those preceded by aura.
Not protective against HIV or other sexually transmitted infections; contraceptive use should be combined with barrier methods for STD prevention.
Risk of hyperkalemia, particularly in patients with renal impairment or those taking potassium-sparing drugs or supplements.
Increased risk of depressive symptoms or mood alterations during therapy.
Risk of breakthrough bleeding; persistent bleeding should prompt medical evaluation.
Potential for increased intraocular pressure in patients with glaucoma.
Rare but serious allergic reactions including angioedema and anaphylaxis have been reported.
Possible alterations in glucose tolerance requiring monitoring in diabetic patients.
Patients with a history of hormone-sensitive cancers should avoid use.

Contraindication

Known or suspected pregnancy or breastfeeding.
History of or current thrombosis such as deep vein thrombosis or pulmonary embolism.
History or presence of ischemic heart disease, cerebrovascular disease, or severe peripheral arterial disease.
Uncontrolled hypertension or hypertensive retinopathy.
Major surgery necessitating prolonged immobilization without appropriate prophylaxis.
Severe liver disease, including liver tumors or acute viral hepatitis.
Known or suspected hormone-dependent malignancies such as breast or endometrial cancer.
Migraine headaches with focal neurological symptoms (aura).
Known hypersensitivity to drospirenone, ethinyl estradiol, or any component of the formulation.
Hyperkalemia or conditions predisposing to elevated potassium levels.
Porphyria.
Disorders of coagulation or patients on anticoagulation therapy with unstable response.
Idiopathic vaginal bleeding of undetermined origin.
Use concomitantly with hepatitis C medications containing ombitasvir/paritaprevir/ritonavir and dasabuvir due to risk of elevated liver enzymes.
Severe renal impairment or kidney failure.
History of jaundice related to pregnancy or previous hormonal contraceptive use.

Drug Interactions

Enzyme inducers such as phenytoin, carbamazepine, phenobarbital, topiramate, oxcarbazepine, primidone, and felbamate which may reduce contraceptive plasma concentrations and efficacy.
Antibiotics including tetracycline, minocycline, and ampicillin which may alter gut flora and reduce enterohepatic recirculation of ethinyl estradiol.
Antifungal agents such as ketoconazole, itraconazole, voriconazole, fluconazole, and griseofulvin which may affect metabolism of contraceptive hormones.
Hepatitis C antivirals containing ombitasvir, paritaprevir, ritonavir, and dasabuvir significantly increasing risk of liver enzyme elevations when combined with Yaz.
Blood pressure agents including lisinopril, captopril, enalapril, valsartan, and losartan which may have additive or opposing pharmacodynamic effects.
Diuretics such as spironolactone, which may increase hyperkalemia risk when combined with drospirenone's potassium-sparing effect.
Potassium supplements or potassium-sparing diuretics increasing the risk of hyperkalemia.
Chronic use of NSAIDs including acetaminophen, ibuprofen, and naproxen may interact with dosing or renal function.
St. John's wort inducing CYP3A4, potentially reducing contraceptive effectiveness and increasing risk of unintended pregnancy.
Anticoagulants like heparin or enoxaparin requiring careful monitoring due to hormonal effects on coagulation.
Potential interactions with other hormonal therapies or supplements containing estrogen or progestins.
Drugs altering liver enzyme metabolism affecting serum concentrations of both drospirenone and ethinyl estradiol.
Concomitant medications altering gastrointestinal motility or absorption impacting oral contraceptive bioavailability.
Herbal supplements and over-the-counter medications with enzyme-inducing or inhibiting properties.
Medicines affecting potassium homeostasis necessitating regular electrolyte monitoring.

Preparations Of The Drug

Oral tablets containing 3 mg drospirenone and 0.02 mg ethinyl estradiol as marketed under the brand name Yaz.
Packaged in 28-day blister packs with 24 active hormone tablets followed by 4 inactive placebo tablets.
Unit dose form designed for once-daily administration.
Stored at room temperature, protected from moisture and heat.
Available in prescription-only formulations intended for female contraceptive use and treatment of related hormonal disorders.
Non-interchangeable with other drospirenone/ethinyl estradiol products due to differing estrogen amounts and dosing regimens.
Formulations include inactive ingredients to enhance stability, palatability, and patient compliance.
Commercially manufactured with standardized hormone content to ensure consistent pharmacokinetics.
Accompanied by patient information leaflets detailing dosing instructions, contraindications, and precautions.
Offered under various other brand names with distinct compositions; Yaz specific formulation has low-dose estrogen to reduce side effects.
Packaging designed for patient convenience with clear labeling for daily administration follow-up.
No available over-the-counter versions; prescription monitored due to risks associated with use.
Manufactured with quality control standards complying with regulatory authority approvals.
Distributed globally with consideration of regulatory variations and available generic alternatives.